Paper Details
- Home
- Paper Details
Original Abstract of the Article :
This case report describes for the first time acute coronary syndrome in a 67-year old patient after oral intake of naratriptan for migraine. So far in the literature, only sumatriptan, zolmitriptan and frovatriptan have been described to cause acute coronary syndromes. A 67-year old Swiss woman wit...See full text at original site
Dr.Camel's Paper Summary Blogラクダ博士について
ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。
* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。
引用元:
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2706221/
データ提供:米国国立医学図書館(NLM)
Triptans and Troponin: A Case Report of Acute Coronary Syndrome
The desert of cardiovascular health can be unpredictable, with sudden storms of heart attacks and strokes. This case report explores the potential link between triptans, a class of medications used to treat migraines, and acute coronary syndrome (ACS). The report details the case of a 67-year-old woman who experienced chest pain after taking naratriptan, a type of triptan. The woman's ECG showed abnormalities, and troponin levels, a marker of heart damage, were elevated. While coronary angiography revealed normal coronary arteries, the researchers suggested that naratriptan-induced coronary vasospasms may have triggered the ACS.
Navigating the Risks of Triptans: A Cautionary Tale
The case report highlights the potential for triptans to induce ACS, even in individuals without pre-existing heart disease. This finding serves as a cautionary tale, emphasizing the importance of careful monitoring and consideration of patient history when prescribing triptans. Like encountering a hidden sandstorm in a seemingly tranquil desert, this case reminds us that even seemingly safe medications can have unexpected side effects.
Staying Vigilant: A Balanced Approach to Migraine Treatment
This case report underscores the need for a cautious approach to migraine treatment, particularly in individuals with potential cardiovascular risk factors. It is essential to consult with your healthcare provider to discuss your individual health needs and determine the best treatment options for you. By carefully navigating the landscape of migraine treatment, we can work to minimize the risks and maximize the benefits.
Dr. Camel's Conclusion
This case report sheds light on the potential complications associated with triptan use. While triptans can be effective in treating migraines, their potential to induce ACS underscores the importance of careful monitoring and individualized treatment plans. As we continue to explore the desert of migraine treatments, we must remain vigilant and prioritize patient safety.
Date :
- Date Completed 2009-09-01
- Date Revised 2021-10-20
Further Info :
Related Literature
English
This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.